GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma - Nature

Chimeric antigen receptor (CAR) T cells for antitumour therapy ‘armoured’ with a dominant-negative TGFβ receptor II show enhanced efficacy and tolerable safety in patients with advanced hepatocellular carcinoma who have developed resistance or not responded to previous treatment.

Raccontata danature.com